Bio-process Technology Market

Executive Summary

Bio-process Technology Market was valued at US $80.50 billion in 2021 and is projected to grow at 13.33% CAGR over the forecast period to reach US $170.54 billion by 2027. Bio-process Technology Market represented US $17.82 billion opportunity over 2019-2021 and estimated to create US $90.04 billion opportunity in 2027 over 2021.

Bio-process Technology from Consainsights analyses the Bio-process Technology Market in the Life Sciences industry over the forecast period to 2027.

Bio-process Technology research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Bio-process Technology segmentation includes Product, Application, End-User and Geography.

Based on the Product, the Bio-process Technology analysis covers Instruments, Consumables and Accessories.

In Product segment, Instruments segment has highest cagr growth of 11.76%.

Based on the Application, the Bio-process Technology analysis covers Recombinant Proteins, Monoclonal Antibodies, Antibiotics, Others.

In Application segment, Recombinant Proteins segment has highest cagr growth of 11.76%.

Based on the End-User, the Bio-process Technology analysis covers Biopharmaceutical Companies, Contract Manufacturing Organizations, Academic Research Institute, Others.

In End-User segment, Biopharmaceutical Companies segment has highest cagr growth of 11.76%.

Based on the region, the Bio-process Technology analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include F. Hoffmann-La Roche Ltd, Sartorius Group, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Gonotec GmbH, Advanced Instruments, KNAUER Wissenschaftliche Gerate GmbH, Merck KGaA, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Instruments segment has the highest revenue of US $40.45 billion and is expected to grow at CAGR of 11.76% by 2027 Instruments segment has highest cagr growth of 11.76%.

Instruments

Instruments segment was valued at US $31.50 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $85.70 billion by 2027. Instruments segment represented US $8.96 billion opportunity over 2019-2021 and estimated to create US $45.25 billion opportunity in 2027 over 2021.

Consumables and Accessories

Consumables and Accessories segment was valued at US $31.18 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $84.84 billion by 2027. Consumables and Accessories segment represented US $8.87 billion opportunity over 2019-2021 and estimated to create US $44.79 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Recombinant Proteins segment has the highest revenue of US $33.20 billion and is expected to grow at CAGR of 11.76% by 2027 Recombinant Proteins segment has highest cagr growth of 11.76%.

Recombinant Proteins

Recombinant Proteins segment was valued at US $25.85 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $70.33 billion by 2027. Recombinant Proteins segment represented US $7.35 billion opportunity over 2019-2021 and estimated to create US $37.13 billion opportunity in 2027 over 2021.

Monoclonal Antibodies

Monoclonal Antibodies segment was valued at US $18.35 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $49.93 billion by 2027. Monoclonal Antibodies segment represented US $5.22 billion opportunity over 2019-2021 and estimated to create US $26.36 billion opportunity in 2027 over 2021.

Antibiotics

Antibiotics segment was valued at US $14.54 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $39.56 billion by 2027. Antibiotics segment represented US $4.13 billion opportunity over 2019-2021 and estimated to create US $20.89 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $3.94 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $10.71 billion by 2027. Others segment represented US $1.12 billion opportunity over 2019-2021 and estimated to create US $5.66 billion opportunity in 2027 over 2021.

End-User

Introduction

In 2021, Biopharmaceutical Companies segment has the highest revenue of US $45.03 billion and is expected to grow at CAGR of 11.76% by 2027 Biopharmaceutical Companies segment has highest cagr growth of 11.76%.

Biopharmaceutical Companies

Biopharmaceutical Companies segment was valued at US $35.06 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $95.40 billion by 2027. Biopharmaceutical Companies segment represented US $9.97 billion opportunity over 2019-2021 and estimated to create US $50.37 billion opportunity in 2027 over 2021.

Contract Manufacturing Organizations

Contract Manufacturing Organizations segment was valued at US $13.87 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $37.75 billion by 2027. Contract Manufacturing Organizations segment represented US $3.94 billion opportunity over 2019-2021 and estimated to create US $19.93 billion opportunity in 2027 over 2021.

Academic Research Institute

Academic Research Institute segment was valued at US $8.38 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $22.81 billion by 2027. Academic Research Institute segment represented US $2.38 billion opportunity over 2019-2021 and estimated to create US $12.04 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $5.36 billion in 2019 and is projected to grow at 11.76% CAGR over the forecast period to reach US $14.58 billion by 2027. Others segment represented US $1.52 billion opportunity over 2019-2021 and estimated to create US $7.70 billion opportunity in 2027 over 2021.